mRNA 平台市场 - 全球产业规模、份额、趋势、机会和预测，按适应症、可用性、mRNA 类型、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球 mRNA 平台市场价值为 73 亿美元，预计到 2030 年将以 3.56% 的复合年增长率成长。 mRNA（信使 RNA）平台是一项先进的生物技术创新，它使合成 RNA 分子能够向细胞传递遗传指令，从而促进特定蛋白质的产生。这种方法在疫苗开发中已取得显着成功，并正在扩展到一系列疾病的治疗。值得注意的是，2023 年 9 月，BioNTech SE 与 CEPI 合作，加速开发基于 mRNA 的 Mpox 疫苗，凸显了该平台在应对新出现的传染病威胁方面的重要性。透过模仿 RNA 在体内的自然作用，合成的 mRNA 序列被设计来促进免疫反应或支持治疗性蛋白质的生产。这些技术由于其适应性、发展速度和有效性而越来越多地采用，特别是在公共卫生紧急情况和个人化医疗应用中。

关键市场驱动因素

技术进步

主要市场挑战

疫苗犹豫和错误讯息

主要市场趋势

虚拟审判数量的增加

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球 mRNA 平台市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按适应症（自体免疫疾病、癌症、传染病、罕见疾病、呼吸系统疾病）
  • 依可用性（预防性疫苗、治疗性药物、治疗性疫苗）
  • 依 mRNA 类型（核苷修饰 mRNA、自扩增 mRNA、未修饰 mRNA）
  • 按最终用户（医院和诊所、製药公司、研究机构）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区 mRNA 平台市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第七章：欧洲mRNA平台市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第八章：北美mRNA平台市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第九章：南美mRNA平台市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲 mRNA 平台市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球 mRNA 平台市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Amgen Inc. AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• Baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

第 17 章：策略建议

第18章调查会社について・免责事项

The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected to grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Market Players

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

• Autoimmune Diseases
• Cancer
  • Personalized Treatment
  • Single Cancer Focused
• Infectious Diseases
• Rare Diseases
• Respiratory Diseases

mRNA Platform Market, By Usability:

• Prophylactic Vaccines
• Therapeutic Drugs
• Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

• Nucleoside-Modified mRNA
• Self-Amplifying mRNA
• Unmodified mRNA

mRNA Platform Market, By End-User:

• Hospitals & Clinics
• Pharmaceutical Companies
• Research Organization

mRNA Platform Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
  • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
  • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
  • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Usability
  • 6.2.3. By mRNA Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China mRNA Platform Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Usability
      • 6.3.1.2.3. By mRNA Type
      • 6.3.1.2.4. By End User
  • 6.3.2. India mRNA Platform Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Usability
      • 6.3.2.2.3. By mRNA Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Australia mRNA Platform Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Usability
      • 6.3.3.2.3. By mRNA Type
      • 6.3.3.2.4. By End User
  • 6.3.4. Japan mRNA Platform Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Usability
      • 6.3.4.2.3. By mRNA Type
      • 6.3.4.2.4. By End User
  • 6.3.5. South Korea mRNA Platform Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Usability
      • 6.3.5.2.3. By mRNA Type
      • 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Usability
  • 7.2.3. By mRNA Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France mRNA Platform Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Usability
      • 7.3.1.2.3. By mRNA Type
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany mRNA Platform Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Usability
      • 7.3.2.2.3. By mRNA Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Spain mRNA Platform Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Usability
      • 7.3.3.2.3. By mRNA Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy mRNA Platform Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Usability
      • 7.3.4.2.3. By mRNA Type
      • 7.3.4.2.4. By End User
  • 7.3.5. United Kingdom mRNA Platform Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Usability
      • 7.3.5.2.3. By mRNA Type
      • 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Usability
  • 8.2.3. By mRNA Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States mRNA Platform Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Usability
      • 8.3.1.2.3. By mRNA Type
      • 8.3.1.2.4. By End User
  • 8.3.2. Mexico mRNA Platform Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Usability
      • 8.3.2.2.3. By mRNA Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Canada mRNA Platform Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Usability
      • 8.3.3.2.3. By mRNA Type
      • 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Usability
  • 9.2.3. By mRNA Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil mRNA Platform Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Usability
      • 9.3.1.2.3. By mRNA Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina mRNA Platform Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Usability
      • 9.3.2.2.3. By mRNA Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia mRNA Platform Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Usability
      • 9.3.3.2.3. By mRNA Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Usability
  • 10.2.3. By mRNA Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa mRNA Platform Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Usability
      • 10.3.1.2.3. By mRNA Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia mRNA Platform Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Usability
      • 10.3.2.2.3. By mRNA Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE mRNA Platform Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Usability
      • 10.3.3.2.3. By mRNA Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amgen Inc. AstraZeneca PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Asuragen, Inc.
• 16.3. Catalent Pharma Solutions
• 16.4. Arcturus Therapeutics, Inc.
• 16.5. BioNTech AG
• 16.6. CRISPR Therapeutics Inc.
• 16.7. AKESOgen, Inc.
• 16.8. Baseclick GmbH
• 16.9. Accent Therapeutics Inc.
• 16.10.Accanis Biotech F&E GmbH & Co KG

17. Strategic Recommendations

18. About Us & Disclaimer